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Abstract  
Background. Systemic lupus erythematosus (SLE) has 
diverse clinical manifestations, including renal and non-
renal. Renal manifestation is related to significant 
morbidity and mortality. SLE is also characterized by 
serological aberrations, including decrease levels of 
complement 3, complement 4 and increase levels of anti-
dsDNA, but the association of them with clinical 
manifestations including renal and non-renal is unclear. 
This study investigated the associations of complement 
3, complement 4 and anti-dsDNA levels with renal and 
non-renal manifestations in SLE patients.  
Method. A cross-sectional study was conducted in the 
Polyclinic of Rheumatology, Dr. Saiful Anwar Hospital 
Malang. A number of 43 subjects fulfilled the 1997 
American College of Rheumatology criteria participated in 
this study that consisted of 11 patients with renal 
manifestation and 32 patients with non-renal 
manifestations. Serum complement 3 and complement 4 
levels were measured using immunoturbidimetry, and 
serum anti-dsDNA levels were measured using enzyme-
linked immunosorbent assays (ELISA). The independent 
T-test was used to compare complement 3 levels  
and the Mann-Whitney U test was used to compare 
complement 4 and anti-dsDNA levels between groups. 
Result. SLE with renal manifestation had significant lower 
levels of serum complement 3 compare to non-renal 
manifestations (mean ± SD: 71.27 ± 32.65 mg/ dL and 
94.47 ± 26.29 mg/dL respectively, p=0.022). SLE with 
renal manifestation also had significantly lower levels of 
serum complement 4 compare to non-renal manifestations 
(mean ± SD: 14.55 ± 8.20 mg/dL and 25.50 ± 11.05 mg/dL 
respectively, p=0.002). Conversely, SLE with renal 
manifestation had significantly higher levels of serum anti-
dsDNA compare to non-renal manifestations (mean ± SD: 
249.27 ± 240.34 IU/mL and 109.91 ± 166.11 IU/mL 
respectively, p=0.014). Conclusion. SLE patients with 
renal manifestation have significantly lower levels of serum 
complement 3 and complement 4 and a higher level of 
serum anti-dsDNA than SLE patients with non-renal 
manifestations. Keywords: complements, anti-dsDNA, 
immune complex, renal manifestation 
 
 
 
Introduction 
Systemic lupus erythematosus (SLE) is a 
multisystemic autoimmune disorder with broad 
spectrum clinical manifestations in almost all organs.1 
Renal manifestation is an important predictor of poor 
outcome and is regarded as one of the most severe 
SLE manifestations and may have devastating 
consequences at any age.2-5 Higher rates of renal 
manifestation, one of main systems involved in death, 
were occurred more in Asians than in whites, with 21–
65% occurred at diagnosis and 40–82% all over 
time.6,7 The mortality risk increased with longer 
disease duration.8  
Renal manifestation of SLE, also named as lupus 
nephritis, is an immune complex (IC) 
glomerulonephritis. ICs and complement activation 
mediates the function of immune effector and leads to 
tissue injury. Failure in immune complex cleaning 
results in tissue deposition and tissue injury.1 Large 
aggregates and insoluble ICs are cleared by phagocyte 
system in the liver and spleen. Tissue deposition of 
soluble ICs is influenced by systemic factors, their 
physiochemical properties and hemodynamics of 
tissue.4  
Increased titers of anti-dsDNA, along with 
hypocomplementemia, was associated with the 
disease activity, but there were only a few data about 
its association with renal manifestation.5 The 
involvement of the complement system in 
autoimmune diseases is well known but its 
mechanism is not clear whether it is a cause or a 
consequence of autoimmune diseases.6 Deficiencies in 
classical pathway complement components 
predisposed patients to SLE and activation of 
complement by ICs is proven in SLE.6,9 Complement 
3 and complement 4 levels reflect the circulating 
complements.8 Studies to determine whether 
complement 3, complement 4 and anti-dsDNA serum 
levels reflect renal manifestation had conflicting 
results. In this study, we investigated the association 
of serum complement 3, complement 4 and anti-
dsDNA levels with renal and non-renal manifestations 
of SLE. 
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Method  
Patients 
Forty-three patients were included in this cross-sectional study 
during the period May 2013 to May 2015 at the Polyclinic of 
Rheumatology at Dr. Saiful Anwar Hospital Malang, Indonesia. 
All the patients fulfilled at least four of 11 American College of 
Rheumatology (ACR) 1997 SLE criteria (malar rash, discoid 
rashes, photosensitivity, oral ulcers, non-erosive arthritis, 
pleuritis or pericarditis, renal disorders, neurologic disorders, 
hematologic disorders, immunologic disorders and positive 
antinuclear antibody).10 This study excluded subjects suffering 
from other autoimmune diseases, severe infection/ sepsis, chronic 
infection, hypertension and diabetes mellitus. This research was 
approved by the Ethical Committee of Dr. Saiful Anwar Hospital. 
 
Clinical Measurement 
Renal manifestation is defined as evidence of lupus nephritis 
(renal disorder in the ACR 1997 SLE criteria list). Lupus 
nephritis is clinical and laboratory manifestations that meet 
ACR 1997 criteria specifically for renal, which includes: 
persistent proteinuria >0.5 g per day or greater than 3+ by 
dipstick and/or cellular casts including red cell, hemoglobin, 
granular, tubular or mixed (10); and includes also the criteria 
from review of the ACR 1997, which a spot urine 
creatinine/protein ratio >0.5 can substitute the 24 hour protein 
measurement, and active urinary sediment (>5 RBC/hpf, >5 
WBC/hpf in the absence of infection, or cellular casts limited 
to RBC or WBC casts) can substitute cellular casts.7 Non-renal 
manifestations are all other criteria in ACR 1997 except for 
renal disorders. 
 
Laboratory Measurement  
Complements 
Measurement of serum complement 3 and complement 4 
levels was performed using immunoturbidimetry (reagents 
from Abbott®, catalog number: 9D96-21 and 9D97-21, 
respectively). Complement 3 or complement 4 in the sample 
were combined with antibodies to complement 3 or 
complement 4 to form immune complexes. These complexes 
increased the intensity of light scatter in the reaction cuvette. 
The turbidimeter monitored the change in absorbance at 340 
nanometers which was proportional to the concentrations of 
complement 3 or complement 4. Complement 3 or 
complement 4 concentrations were automatically calculated 
from the calibration curves. The normal range for serum 
complement 4 is 10-40 mg/dl. The normal range for serum 
complement 3 is 85-160 mg/dl for person aged 12-18 years 
old, 82-160 mg/dl for person aged 20s years old, 84-160 mg/ 
dl for person aged 30s years old and 90-170 mg/dl for person 
aged 40-70 years old. 
 
Anti-dsDNA 
Measurement of quantitative serum IgG anti-dsDNA levels was 
performed using ELISA test system (kit from EUROIMMUN®, 
catalog number: EA 1572-9601 G). The test was based on an 
indirect enzyme linked immune reaction. Antibodies in the serum 
bound to the antigen coated on the 
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reaction wells. After incubation, a washing removed unbound 
and unspecifically bound components. Then, enzyme was 
conjugated to the antibody-antigen-complexes. After 
incubation, a second washing removed unbound enzyme. 
Substrate solution hydrolysed the substrate generating a blue 
coloured product. An acid stopped the reaction generating a 
yellow end-product. The intensity of the yellow color 
measured photometrically at 450 nm correlated with the 
concentration of the antibody-antigen-complex. Serum anti-
dsDNA titer <100 IU/mL is considered as negative and ≥100 
IU/mL is positive. 
 
Other Laboratory Measurements 
Routine laboratory tests from the SLE patients included 
complete blood count (flowcytometry), urinalysis (dipstick 
and microscopic), and plasma ureum and creatinine 
(spectrophotometry). 
 
Statistical Methods 
To compare between groups, we used T-test for normal 
distributed data and Mann-Whitney U test for abnormal 
distributed data. Independent T-test was used to compare 
complement 3 levels between renal and non-renal manifestation 
of SLE. Mann-Whitney U test was used to compare C4 and anti-
dsDNA levels between renal and non-renal manifestations of 
SLE. Continuous variables were expressed as mean ± standard 
deviation. All p values were two-tailed and differences at ≤0.05 
were considered significant. Statistical analysis was performed 
using SPSS 16.0. 
 
Result 
A total of 43 female patients with SLE were enrolled in this 
study with mean age of 34.35 ± 10.35 years old, 11 patients 
(25.58%) with renal manifestation and 32 patients (74.42%) 
with non-renal manifestations. Non-renal SLE subjects 
consisted of 21 patients (48.84%) with musculoskeletal 
disorders, 28 patients (65.12%) with mucocutaneous 
disorders, three patients (6.98%) with neurological disorders 
and 28 patients (65.12%) with hematologic disorders. Baseline 
patient characteristics of the two groups, renal and non-renal 
manifestations of SLE are summarized in Table  
1. Hemoglobin levels in patients with renal manifestation were 
significantly lower than those in patients with non-renal 
manifestations. Other parameters were similar in both groups. 
 
Table 1. Baseline patient characteristics.  
Patient characteristics Renal Non-renal p- 
 (n=11) (n=32) value 
Age in years; mean (± SD) 31.00 ± 5.53 35.53 ± 11.38 0.091 
Race; n (%)      
Asian 11 (100) 32 (100)  
Ethnicity; n (%)      
Javanese 11 (100) 32 (100)  
Disease duration in months 24 (12 - 38) 26.35 ± 13.37 0.561 
Blood pressure:      
Systole in mmHg 117.10 (100 - 160) 117.10 ± 12.49 0.670 
Diastole in mmHg 77.00 ± 13.89 74.19 ± 8.72 0.436 
Hemoglobin (g/dL) 10.75 ± 2.50 13.18 (11.3 - 16.5) 0.005 
Lymphocyte (/µL) 1,324 ± 720 1,575 ± 1,008 0.750 
 
Values are the mean (±SD), median (25% quartile-75% 
quartile), or number (%) of patients. 
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The mean of serum complement 3 levels was normal in patients 
with non-renal manifestations, but low in renal manifestation 
(Figure 1A). The mean of serum complement 4 levels was normal 
in patients with non-renal and renal manifestations, but 
profoundly lower in patients with renal than non-renal 
manifestations (Figure 1B). There was no patient had decreased 
serum complement 4 without decreased serum complement 3. 
The mean of serum anti-dsDNA levels in patients with renal and 
non-renal manifestations was positive (>100 IU/mL), but it was 
significantly higher in patients with renal than non-renal 
manifestations (Figure 1C). The findings are summarized in 
Table 2. 
 
Table 2. The levels of serum complement 3, complement 4 and 
anti-dsDNA in patients with renal and non-renal manifestations. 
Parameters Renal Non-renal p-value 
Complement 3 in mg/dL; 71.27 ± 32.65 94.47 ± 26.29 0.022 
mean (± SD)   0.002 
Complement 4 in mg/dL; 14.55 ± 8.20 25.50 ± 11.05 0.014 
mean (± SD)    
Anti-dsDNA in IU/mL; 242.7 ± 240.3 109.9 ± 166.11  
mean (± SD)    
Negative anti-dsDNA; n (%) 4 (3.36) 21 (65.62)  
Normal complement 3/ 3 (27.7) 17 (3.12)  
complement 4; n (%)    
Low complement 3/normal 5 (45.45) 14 (43.75)  
complement 4; n (%)    
Normal complement 3/low - -  
complement 4; n (%)    
Low complement 3/ 3 (27.27) 1 (3.12)  
complement 4; n (%)    
 
Values are the mean (± SD), median (25% quartile-75% 
quartile), or number (%) of patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A) Serum complement 3 levels in patients with renal and 
non-renal manifestations. B) Serum complement 4 levels in 
patients with renal and non-renal manifestations. C) Serum anti-
dsDNA levels in patients with renal and non-renal manifestations.  
 
 
Discussion 
The results of this study indicate that the levels of serum 
complement 3 and complement 4 were significantly lower in SLE 
patients with renal manifestation compared to non-renal 
manifestations and show insights into the role of complements in 
renal manifestation of SLE. Immune complex (ICs)-mediated 
activation of complements in lupus nephritis is shown in 
experimental and study in human with SLE.6 Increased 
accumulation of soluble ICs in renal manifestation was influenced 
highly by plasma filtration in glomerular capillaries,11 fixed 
negative charges on the filtration barrier and physiochemical 
properties of ICs (charge, valence, size, antibody affinity, 
immunoglobulin class).4 Interactions between fixed anionic sites 
and ICs could be an important factor in glomerular binding. 
Julkunen found that active nephritis was correlated significantly 
with low levels of complement 3 and complement 4.5 Jacob 
demonstrated that the degree of renal pathology was consequent 
to the absence of glomerular complement 3 deposition.12 Our 
study showed that not all patients with renal manifestation had 
low serum complement 3 and complement 4 levels, it might be 
due to the optimal treatment they received.  
Hemoglobin levels in the group of patients with renal 
manifestation were significantly lower than those without renal 
manifestation. This could be caused by the effect of decreased 
kidney function on the synthesis of hemoglobin or by SLE itself 
due to anemia of chronic disease or hemolysis, but it was not 
examined further in this study. Many studies showed that 
complements played role in autoimmune hemolytic anemia 
(AIHA) in SLE.13 In SLE patients with AIHA, CD55 and CD59, 
proteins play role as protection against complement-induced cell 
lysis on erythrocytes, were underexpressed.14,15 Complement 
receptor 1 (CR1), a regulatory protein of complement, were also 
found lost on erythrocytes of SLE patients.16,17 Moreover, 
complement-dependent autoantibodies were found to suppress 
bone marrow progenitor cells in SLE patients with aplastic 
anemia.18-20 Study in animal model had the same result, that 
NZB lupus prone mice produced anti  erythrocyte 
autoantibodies.21 
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In this study, serum complement 3 levels were profoundly 
lower than complement 4 in patients with renal 
manifestations, suggested that the damage manifested as a 
renal disorder involved amplified complement 3 activation, 
and it mean predominantly the alternative pathway.22 There 
are several explanations for this. complement 3 might be 
directly activated by urine pH or ammonia released from 
stressed epithelial cells or by convertase-like enzymes in the 
apical brush border of proximal tubule which deficient in 
complement regulatory proteins.23-25 Disease severity is lower 
when an intact complement system is absent.26 A different 
result from a study by Hussain in 2008, demonstrated that 
complement 4 was depleted more than complement 3. They 
found that complement 4 levels were low in most of the lupus 
nephritis patients. Low complement 4 levels may be falsely 
regarded as partial defects in complement 4A or/and 
complement 4B which reduced total levels of complement 4. 
Decreased synthesis or increased catabolism of complement 4 
without complement activation may also explain low 
complement 4 levels.8 Other study found that low levels of 
complement 3 and complement 4 were specific for lupus 
nephritis, but had low sensitivity.26  
This study also found that serum anti-dsDNA levels were 
elevated in patients with renal and non-renal manifestations. 
However, serum anti-dsDNA levels in renal manifestation were 
significantly higher than those of non-renal manifestations. 
Increased anti-dsDNA levels had been shown by many, but not 
all, studies to be the predictors of disease flares in SLE. In some 
cohorts, serum anti-dsDNA levels were correlated to nephritis 
with progression to end-stage renal disease.27 Patients with lupus 
nephritis usually have antibodies against dsDNA and high avidity 
anti-DNA that activates complements strongly. High avidity anti-
DNA also occurs in proliferative more than membranous lupus 
nephritis.26  
In this study, 36.36% of patients with renal manifestation had 
negative serum anti-dsDNA. The possible cause is a delayed 
response in the early stages of renal manifestation.28 Another 
possibility is the design of assay had significant influence on anti-
dsDNA type, because of different nature and ability to detect 
subtypes of anti-dsDNA with distinct avidity. At least three 
factors are contributing to the pathogenicity of anti-dsDNA: the 
avidity, the cross-reactivity with alpha-actinin in renal and the 
specificity for individual DNA molecules.28,29 Human IgG 
consists of four subclasses: IgG1, IgG2, IgG3 and IgG4, each has 
a different heavy chain.30 Baudino found that IgG3 subclass of 
anti-dsDNA was highly pathogenic and induced lupus-like 
nephritis.31 Although the occurrence of anti-dsDNA subtypes 
with difference pathogenicity is widely accepted, the mechanisms 
and conditions leading to a dominant synthesis of a subtype are 
still unknown.28 Our findings may suggest that renal and non-
renal SLE have difference pathomechanism, whereas 
complements activation and anti-dsDNA play a more prominent 
role in renal SLE than in non-renal SLE. Further understanding 
of the role of complements in renal manifestation requires a 
multivariate approach, with additional complement-related 
variables. 
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Conclusion 
SLE patients with renal manifestation have significantly lower 
levels of serum complement 3 and complement 4 and higher level 
of serum anti-dsDNA than SLE patients with non-renal 
manifestations. This findings suggest that complement activation 
and anti-dsDNA have more prominent role in disease mechanism 
in renal SLE than in non-renal SLE. 
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